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Summary 
We have recently described a monoclonal antibody (mAb) 4G4 recognizing a 70-kD molecule 
constitutively expressed on human endothelial cells and on subpopulations oflymphocytes. We 
showed  that  this  molecule, which  we  named  lymphocyte-vascular adhesion  protein  2  (L- 
VAP-2),  mediates lymphocyte adhesion to  cultured endothelial cells.  Protein sequencing of 
tryptic peptides from immunoaflinity-purified L-VAP-2 revealed sequence identity between L- 
VAP-2 and CD73 (ecto-5'-nucleotidase, E.C.3.1.3.5), and COS cells transfected with a CD73 
cDNA were positively stained with the mAb 4G4, which recognizes L-VAP-2. mAb 4G4 was 
also able to partially inhibit the ecto-5'-nucleotidase activity of peripheral blood lymphocytes. 
Moreover, cross-precipitation studies performed with mAb 4G4 and a CD73 workshop mAb 
1E9 showed that these two antibodies recognize the same molecule. Since the tissue  distribu- 
tion and biochemical characteristics of the two molecules are also  similar, we conclude that 
L-VAP-2 and CD73 are the same glycoprotein. Adhesion experiments showed significantly in- 
creased binding of freshly isolated lymphocytes to COS cells transfected with a CD73 cDNA, 
as compared to mock-transfected COS cells, and binding of lymphocytes to CD73-expressing 
COS cells was inhibited by the presence ofmAb 4G4 in the adhesion assay. CD73 is a glycosyl 
phosphatidylinositol-linked molecule previously shown to have a cosignalling role in T  lym- 
phocyte proliferation. Our data suggest that it also has a function in mediating lymphocyte ad- 
hesion to the endothelium. 
T 
he adhesive interactions between, different cells of the 
immune  system  and  reclrculanon  of  lymphocytes 
through different lymphoid organs are mediated by a vari- 
ety  of molecules  belonging  to  several structural  families. 
These adhesion molecules are expressed on the leukocyte 
and/or the endothelial cell surface, or they are part of the 
extracellular matrix. Of these adhesion molecules, the best 
characterized ones belong to the Ig superfamily or the se- 
lectin and  integrin  molecular families  (reviewed in  1-3). 
Several novel adhesion molecules have recently been dis- 
covered, including the P-selectin ligand PSGL-1 (P-selectin 
glycoprotein ligand 1) or the E-selectin hgand ESL-1 (4, 5). 
We  have previously described a  novel adhesion mole- 
cule, lymphocyte-vascular adhesion protein 2  (L-VAP-2), 
which mediates lymphocyte adhesion to the endothelium 
(6). An mAb 4G4 recognizing L-VAP-2 was obtained from 
an  immunization  with  synovial stroma  and  was  used  to 
study the tissue  distribution and the function of the mole- 
cule. L-VAP-2 is constitutively expressed on cultured hu- 
man endothelial cells, as well as on subpopulations oflym- 
phocytes consisting predominantly of B  cells and CD8 + T 
cells. The involvement of L-VAP-2 in lymphocyte binding 
to the endothelium was tested in vitro using cultured hu- 
man umbilical vein endothelial cells (HUVEC) and freshly 
isolated PBL. mAb 4G4 consistently inhibited lymphocyte 
binding to  HUVEC  by ~25%.  In  immunohistochemical 
analyses,  subpopulations of venules stained positively in a 
number of human tissues.  On tonsillar tissue  sections, ves- 
sels, germinal center B cells, and the basal layer of the sur- 
face epithelium expressed L-VAP-2 (6). Immunoprecipita- 
tions from 125I-labeled endothelial cell lysates  showed that 
L-VAP-2  is  a  70-kD  molecule under both reducing and 
nonreducing conditions  (6).  Based  on the  molecular size 
and  the  tissue  distribution,  L-VAP-2 was judged to be  a 
novel molecule among those known to mediate lympho- 
cyte adhesion to the endothelium. 
In the present paper, we report the further characteriza- 
tion of the L-VAP-2 molecule, including the amino acid 
sequence of tryptic peptides obtained from immunoaffin- 
ity-purified protein. Our data on the cellular distribution, 
molecular size,  and the protein sequence of the L-VAP-2 
molecule expressed on endothelial cells were similar to those 
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4G4  also  reacted  specifically with  ecto-5'-NT  COS  cell 
transfectants.  We  therefore  conclude  that  L-VAP-2  and 
ecto-5'-NT are  the  same  molecule. Ecto-5'-NT has  been 
designated  as  lymphocyte  differentiation  antigen  CD73 
and,  although  an  involvement in  several  immunological 
events has been proposed for the molecule (7),  little is still 
known about the exact role of the molecule in lymphocyte 
functions. In this  report,  we  present evidence of a  novel 
role for CD73 in mediating lymphocyte adhesion to endo- 
thelial cells. 
Materials  and Methods 
Cells, Cell Lines and Antibodies.  The HEC endothelial  cell line 
(equivalent to EaHy-926) was a kind gift from Dr. H. Holth6fer 
(University of Helsinki, Helsinki, Finland). The COS-7 cell line 
was  from  the  American Type  Culture  Collection  (Rockville, 
MD).  Human PBL were isolated  using Ficoll-Hypaque (Histo- 
paque-1077;  Pharmacia,  Uppsala,  Sweden).  mAb  4G4  (mouse 
IgG0 recognizes  L-VAP-2 and inhibits the binding of lympho- 
cytes to cultured endothelial cells (6). Anti-CD73 mAb 1E9 was a 
kind gift of Dr. Linda Thompson (Oklahoma Medical Research 
Foundation, Oklahoma  City,  OK).  Irrelevant isotype-matched 
mAb against chicken T cells (3G6) and an mAb against human ",/ 
heavy chain (HB43;  American Type Culture Collection) were 
used as negative controls. 
Immunoa~nity Purification and Protein Sequencing of L-VAP-2. 
For immunoaffinity  purification, 109 HEC cells were lysed in lysis 
buffer (1% Triton X-100, 0.15 M NaC1, 1.5 mM MgC12, 0.01 M 
Tris,  1 mM PMSF, and 1% aprotinin) containing 1 mM PMSF. 
Insoluble material was removed by centrifugation, and the lysate 
was precleared by passing it sequentially through Sepharose CL-4B 
and columns of cyanogen bromide-activated Sepharose 4B beads 
(Pharmacia)  derivatized  with normal mouse serum or irrelevant 
IgGi mAb. The lysate was then incubated with 5 ml of CnBr- 
activated  Sepharose  4B beads  derivatized  with mAb 4G4. After 
washing the beads with washing buffer (100 mM NaC1, 10 mM 
Na2HPO  4, 0.2% sodium deoxycholate,  0.01% SDS, and 1% NP- 
40),  the bound material  was  eluted with 50  ~  triethylamine 
and lyophilized.  The protein was resolved  with SDS-PAGE (5- 
12.5%, nonreduced) and transferred  to polyvinylidine difluoride 
(PVDF)  membrane (ProBlott;  Applied Biosystems,  Inc.,  Foster 
City,  CA)  by electroblotting. The membrane was  stained  with 
Coomassie  blue, and the 70-kD band was excised and subjected 
to  trypsin digestion  (sequencing grade;  Boehringer Mannheim 
GmbH, Mannheim, Germany), as described  by Fernandez et al. 
(9). The peptides  were separated by HPLC  (model 150 A; Ap- 
plied Biosystems) equipped with a Vydac Cl8 column (2.1 ￿  150 
mm).  NH2-terminal sequence analysis of the peptides  was per- 
formed on a protein sequencer (model 477A;  Applied Biosys- 
terns)  equipped  with  an  on-line phenylthiohydantoin (PTH) 
amino acid analyzer (model 120A; Applied Biosystems). 
Isolation  of a  CD73 eDNA  and  Construction  of Expression 
Vectors.  A full-length cDNA encoding CD73 was amplified by 
reverse  transcription (RT) PCR from total  RNA isolated  from 
HEC cells and inserted into the expression vector pcDNA3 (In- 
vitrogen Corp., San Diego, CA). Standard techniques were used 
for the RNA isolation, cDNA synthesis, PCR amplification using 
the  CD73  specific  primers  GGGGATCCAGTTCACGCGC- 
CACAG and CCCTCGAGGCAAGGAGAATTTTTGG,  sub- 
cloning procedures,  and plasmid preparations  (8, 10). 
Transfection of COS Cells.  COS-7 cells were transfected by elec- 
troporation with 20 btg of the CD73 expression  plasmids or 20 
Ixg of the pcDNA3 plasmid (mock transfection).  3 d after trans- 
fection, cells were detached  with 5 ~  EDTA, immunofluores- 
cence stained  as  described  earlier  (6), and L-VAP-2 expression 
was  detected  with  a  FACScan  |  (Becton  Dickinson  &  Co., 
Mountain View, CA). 
Radiolabeling and Immunoprecipitations.  [3SS]methionine/[3SS]cys- 
teine labeling of HEC cells was performed as described previously 
(11).  The  lysates from  the  labeled cells were  precleared  three 
times  with  50-btl  aliquots  of rabbit anti-mouse Ig  derivatized 
protein A-Sepharose beads  (Pharmacia).  For immunoprecipita- 
tions,  15 p,1 of these beads were preloaded with 1 ml 10(1 p,g/ml 
of purified 4G4 or  1E9 or a negative control mAb (3G6).  Pre- 
cleared lysates were mixed with the specifically coupled protein 
A-Sepharose beads and incubated for 4 h at 4~  for each sequen- 
tial  precipitation. After  washing with  washing buffer,  antigens 
were eluted from the beads with 50 txl Laemmli's sample buffer 
containing 5% mercaptoethanol, and were resolved  in 5-12.5% 
SDS-PAGE. 
Phosphatidylinositol-specific Phospholipase C  (PI-PLC)  Treatment. 
Freshly isolated PBL were resuspended  in RPMI in the presence 
or absence of Bacillus thuringiensis PI-PLC (Oxford Glycosystems, 
Abingdon, UK) at 1 U/ml and incubated for 1 h under rotation 
at 37~  Cells were washed twice and immunofluorescence  stain- 
ing for L-VAP-2 expression  was performed as  described  previ- 
ously (6). 
Ecto-5'-NT Inhibition.  Activity of PBL ecto-5'-NT was ana- 
lyzed using a modification of a previously reported method (12, 
13).  [14C]adenosine-5'-monophosphate ([14CLAMP; ICN  Bio- 
medicals,  Inc.,  Irvine, CA)  was  converted into  [14C]adenosine 
and p4C]inosine by PBL ecto-5'-NT in presence  of 30 p~g/ml of 
purified mAb 4G4, anti-CD73 mAb 1E9, or negative control an- 
tibody 3G6. Substrate  and product were separated by thin-layer 
chromatography,  and  the  corresponding radioactivity  was  de- 
tected by autoradiography.  Quantitation was performed by mea- 
suring the intensity of the dots by using the Microcomputer Im- 
aging Device (MCID; Imaging Research Inc., Ontario, Canada). 
Lymphocyte Binding to COS Cells.  PBL were fluorescence  la- 
beled as  described  before  (6), and were  plated  onto  confluent 
monolayers of CD73- and mock-transfected COS  cells ill  96- 
well  tissue  culture plates.  Cells  were  incubated for  45  rain  at 
37~  and fluorescence  in each  well was determined by a fluo- 
rometer (Titertek Fluoroskan; Labsystems, Helsinki, Finland). Non- 
adherent  lymphocytes  were  removed,  and  the  percentage  of 
bound cells was quantitated by comparing the mean fluorescence 
of eight identical wells with bound lymphocytes to the mean flu- 
orescence  of eight unwashed wells. In an other type of adhesion 
assay, CD73-transfected  COS  cells were  plated  on  eight-well 
permanox chamber slides (Nunc, Inc., Naperville,  IL)  that had 
been presoaked  overnight in PBS at 37~  PBL were added onto 
the chamber slides, and incubation was continued at 37~  for 45 
min. The wells were then gently washed twice with warm RPMI 
to  remove unbound lymphocytes,  after  which  immunoperoxi- 
dase staining of the remaining cells was gently performed as de- 
scribed earlier (6). 3% glutaraldehyde  was added to the wells, and 
lymphocyte binding to CD73-positive cells (10-40% of all cells, 
depending on the experiment) vs CD73-negative cells was evalu- 
ated under light microscopy.  To study the effect of mAb 4G4 on 
lymphocyte adherence to CD73-transfected COS cells, PBL and 
the transfected COS cells oil permanox chamber slides were pre- 
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Since L-VAP-2 is abundantly expressed on cultured en- 
dothelial cells, a HEC cell lysate was used for immunoaffin- 
ity purification to  further  characterize  the  molecule.  Pro- 
tein sequencing oftryptic peptides obtained from the purified 
material revealed sequence identity between L-VAP-2 and 
the  CD73  molecule.  The  peptide  sequences  from  tryptic 
peptides  designated tryptic  19,  24,  and  32  yielded amino 
acid sequences VIYPA, LDVLXTK,  and GNVISSXGNPI, 
which are identical to the sequence of CD73 between po- 
sitions 537-541,472-478,  and 298-308,  respectively (8). 
To confirm that L-VAP-2 and CD73  are the same mol- 
ecule, a full-length CD73 cDNA was isolated by R.T-PCP,. 
mAb 
from HEC  cells and used to transfect COS cells. The COS 
cells transfected with  a  CD73  cDNA were  positive when 
stained with  mAb  4G4,  which  recognizes L-VAP-2  (Fig. 
1),  or with an anti-CD73-mAb  1E9,  whereas mock-trans- 
fected COS cells were negative (Fig. 1). 
To  further  demonstrate  that  4G4  mAb  is  recognizing 
CD73,  sequential  immunoprecipitations  were  performed 
with  mAb  4G4  and  the  anti-CD73  mAb  1E9.  Immuno- 
precipitation with protein A-Sepharose coupled with  1E9 
mAb  completely removed  the  70-kD  protein  recognized 
by  mAb  4G4  from  [3SS]methionine/[35S]cysteine-labeled 
HEC  cell  lysate  (Fig.  2).  Similarly,  4G4  completely  re- 
moved the 70-kD protein detected by 1E9 mAb in the first 
round  of immunoprecipitations  (Fig.  2).  In  addition,  the 
1E9  mAb  precipitated a  smaller ~60-kD  protein  (faintly 
visible), which was not recognized by mAb 4G4  and may 
be  a  nonglycosylated precursor of CD73.  AU of the lym- 
phocyte surface  molecules recognized by mAb  4G4  were 
sensitive to  PI-PLC  treatment,  as shown  by immunofluo- 
4G4 
Neg.  Co 
8 
IE9 
mock-  COS-cells 
transfected  transfectect  with 
COS-cells  CD73  cDNA 
treated with mAb 4G4 a hybridoma supernatant or negative con- 
trol antibody (against human y heavy chain or a nonbinding mAb 
3G6).  The adhesion assay and immunoperoxidase staining were 
performed as  described above,  and  the  effect of mAb  4G4  on 
lymphocyte adherence to COS cells expressing CD73 was exam- 
ined by light microscopy in a blind assay, where the number of 
lymphocytes binding to CD73-positive COS cells in presence of 
the  4G4  mAb was  counted  in  six different  microscopic fields. 
This binding was  compared to binding in  the presence of 3G6 
mAb, anti-"/mAb, or medium only (= Neg. Co). 
Statistical Analyses.  The results are expressed as mean values -4- 
SEM. Statistical significance was evaluated by the two-tailed un- 
paired Student's t test in case of adhesion experiments and by the 
paired Student's t test in case of enzyme inhibition experiments. 
10  ~  10'  102  10  s  100  10'  102  103 
Ruorescence Intensity 
Figure 1.  Flow cytometric analysis  of mock-transfected COS cells or 
COS cells transfected with a CD73  cDNA.  COS cells were transfected 
with CD73 cDNA or plasmid only and stained with antibodies 4G4, 1E9 
(a CD73 workshop mAb), and 3G6 (Neg. Co), as described in Materials 
and Methods. 
Figure  2.  mAbs 4G4  and  1E9  cross-precipitate each other.  After 
[35S]methionine/[3SS]cysteine labeling, the  HEC  cells were  lysed. The 
precleared lysate was then sequentially precipitated with the mAbs (indi- 
cated above the individual lanes; 3G6 is a negative control antibody) cou- 
pled to protein A-Sepharose beads via rabbit anti-mouse  Ig. Molecular 
weight standards in kilodaltons are indicated on the right. IP, immuno- 
precipitation. 
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Figure 3.  CD73 expression on PBL is reduced after PI-PLC treatment 
of cells. FACS  |  profiles are shown from (/1) PBL stained with irrelevant 
mAb 3G6, (B) PBL stained with the anti-CD73 mAb 4G4, and (C) PI- 
PLC-treated PBL stained with mAb 4G4. In B, the arrow points to the 
CD73-positive population of  PBL (15% of all cells). 
rescence staining and FACScan  |  analysis (Fig. 3), which in- 
dicates  that  the  molecule is  GPI linked  to the  cell surface 
(CD73 is also GPI linked;  14). Taken together, the protein 
sequencing,  transfections,  cross-precipitations,  and enzyme 
treatment studies,  together with the immunohistochemical 
and biochemical studies  performed  earlier,  unambiguously 
show that L-VAP-2 and CD73 are the same molecule, and 
hereafter we shall designate L-VAP-2 as CD73. 
CD73,  or ecto-5'-NT, is  a  cell-surface  enzyme hydro- 
lyzing extracellular 5'-mononucleotides to the correspond- 
ing nucleosides. The ability ofmAb 4G4 to block the ecto- 
5'NT  activity  of human  lymphocytes  was  also  studied. 
mAb 4G4 reduced the enzyme activity of lymphocytes by 
22 -+ 1.5% as compared to a negative control antibody 3G6 
(Fig. 4,  P  <0.003,  n  =  4), whereas mAb 1E9 reduced the 
ecto-5'-NT activity by 76 -+ 3.5% (P <0.009, n =  3). Dif- 
ferent  mAbs  recognizing  CD73  have  previously  been 
shown to inhibit ecto-5'-NT activity at different levels (7), 
and  the  inhibition  level probably depends  on the  epitope 
that the antibody recognizes, mAb 4G4 seems to recognize 
an  epitope  different  from  that  recognized  by  1E9  mAb, 
since the levels of enzyme inhibition obtained by these two 
antibodies are quite different. It remains to be seen whether 
4G4 mAb binds  to an epitope  recognized by some of the 
previously  characterized  CD73  workshop  mAbs  or  to  a 
novel epitope. 
CD73 has been shown to have a role in several immuno- 
logical phenomena.  It is a maturation marker for B  and T 
lymphocytes (15,  16) and a reduction in ecto-5'-NT activ- 
ity has been described in lymphocytes of patients  suffering 
from  several  immunodeficiency  diseases  (12,  13,  16-18). 
CD73 has been shown to function as a costimulatory mol- 
ecule in generating T  cell proliferation;  an involvement in 
activation  through  the  CD3/TC1K signalling pathway has 
been indicated (19, 20). 
The tissue distribution of CD73, as well as its other char- 
acteristics in lymphocyte functions, has led to the proposal 
that  CD73  could have  a  role  in lymphocyte homing and 
cell adhesion (14).  Until now, however, no functional stud- 
ies have been performed  to  investigate  this  hypothesis.  In 
our previous work, we showed that L-VAP-2 can mediate 
lymphocyte binding to cultured endothelial cells  (6).  Since 
L-VAP-2  and  CD73  are  shown  to  be  identical,  the  data 
from our adhesion  experiments  are  the  first evidence  that 
100 
.0 
.t= 
50 
t- 
r 
3C-6  4C~  1E9 
Figure 4.  Inhibition  of ecto-5'-NT activity obtained by different anti- 
CD73  mAbs.  Conversion  of  [laC]AMP  to  [14C]adenosine and 
[14C]inosine by PBL-ecto-5'NT in the presence of mAbs 4G4, 1E9, and 
3G6 was quantitated as described in Materials and Methods. The results 
shown are the mean of four samples with mAb 4G4 and three samples 
with mAb IE9 from two individual experiments -  SEM. 
CD73  has  a  role  in  mediating  lymphocyte adhesion.  To 
confirm this,  lymphocyte binding to transfected COS cells 
was analyzed. In these experiments,  it was seen that adher- 
ence  was  significantly  increased  to  COS  cells  transfected 
with CD73 eDNA, as compared to mock-transfected COS 
cells  (P =  0.016;  Fig. 5 A). In four individual experiments 
performed with freshly isolated,  fluorescence-labeled  lym- 
phocytes and either mock-transfected or CD73-transfected 
COS cells  (transfection efficiency ~10%), 32 -+ 5% oflym- 
phocytes bound  to  CD73-transfected  COS  cells,  whereas 
only 25  -+ 4% of lymphocytes bound to mock-transfected 
COS cells.  This corresponds to a 28  +  5% increase in lym- 
phocyte binding to CD73-transfected  COS  cells,  as  com- 
pared to mock-transfected COS-cells (Fig. 5 A). Since only 
10%  of COS cells were  expressing CD73 in these  experi- 
ments, we then used another type of binding assay to dem- 
onstrate  that the lymphocytes actually bind to the  CD73 + 
population of COS cells.  In this assay,  after removing un- 
bound  lymphocytes  from  chamber  slides,  the  transfected 
COS cells and the tightly bound lymphocytes were stained 
with  the  mAb 4G4  to visualize  the  CD73 +  COS  cells.  It 
was seen that lymphocytes preferentially bound to the pos- 
itively  stained  COS  cells  expressing  CD73,  whereas  the 
CD73-  COS cells  had significantly fewer lymphocytes at- 
tached to them  (Fig.  5  B).  The nature  of this lymphocyte 
binding  to  CD73 +  COS  cells  was  quite  strong,  since  the 
lymphocytes were not detached during the gentle washing 
procedures included in the peroxidase staining protocol af- 
ter the binding assay.  In some of the  experiments,  CD73- 
transfected COS cells and lymphocytes were pretreated with 
the mAb 4G4, and an inhibition of  41  +  7% could be seen in 
lymphocyte binding to CD73 + COS cells,  as compared to 
the binding of cells pretreated with a negative control anti- 
body or medium  only  (Fig.  5  C).  Thus,  we  have  shown 
here that CD73 is involved in mediating lymphocyte adhe- 
sion by demonstrating that lymphocytes bind more avidly 
to CD73 + than to CD73- COS cells and by blocking lym- 
phocyte adhesion  to  CD73 +  COS  cells  by an  anti-CD73 
antibody. 
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Figure  5.  Involvement of CD73  in lymphocyte 
binding  to COS cells. (A) Lymphocytes adhere more 
readily to COS cells transfected with CD73 than to 
mock-transfected  COS  cells. Binding  of  fluores- 
cence-labeled  lymphocytes  to  COS  cells was  mea- 
sured by incubating lymphocytes on monolayers of 
mock-transfected or CD73-transfected COS cells for 
45 min at 37~  Data are given as the mean relative 
adherence  ratio  of four  individual  experiments  + 
SEM. (B) Lymphocytes specifically  adhere to CD73- 
expressing COS cells. COS cells were transfected by 
electroporation  (transfection efficiency  =  10-40%), 
plated on permanox chamber slides, and the adhesion 
assay with lymphocytes was performed  as described 
in Materials and Methods.  After this, the cells were 
stained using 4G4 as a first-stage antibody to visualize 
CD73-expressing  COS cells, and lymphocyte  bind- 
ing to CD73  § vs CD73- COS cells was evaluated. 
Shown  is a photomicrograph  of a positively stained 
COS cell (long arrow) with several lymphocytes attached to it (arrowheads). Several CD73-negative  COS cells (short arrows) are devoid oflymphocytes.  (C) 
Binding oflymphocytes to CD73-expressing COS cells is inhibited by 4G4 mAb. The binding  assays with a preincubation with either the mAb 4G4 or 
a negative control (mAb 3G6, anti-~/mAb or medium only) were performed with lymphocytes and CD73-transfected  COS cells on eight-well per- 
manox chamber slides as described in Materials and Methods. The results shown are from three individual experiments --- SEM. 
The  exact  mechanisms  responsible  for  CD73-mediated 
adhesion are not clear at the moment. Either direct recep- 
tor-ligand binding or CD73-mediated  intraceUular signal- 
ling controlling the  function of other  adhesion  molecules 
may be responsible for the lymphocyte adhesion observed; 
antibody binding to  CD73  was  recently shown to  induce 
tyrosine  phosphorylation  and  dephosphorylation  of lym- 
phocyte  intracellular proteins,  the  identities  of which  are 
unknown at the present time (21). Interestingly, extraceUu- 
lar  adenosine,  which  in vivo  is  produced  by  ecto-5'-NT 
activity, has previously been shown to  regulate  neutrophil 
binding to the endothelium (22). The enzymatic activity of 
CD73  may therefore  also be involved in controlling lym- 
phocyte adhesion. 
In conclusion, we have shown that L-VAP-2 is identical 
to CD73. We also directly demonstrate the involvement of 
CD73 in mediating lymphocyte adhesion by blocking lym- 
phocyte  binding to  CD73-expressing  COS  cells  with  an 
antibody against CD73.  The exact mechanisms responsible 
for this novel function are under investigation. 
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